Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 87 points (0.5%) at 16,266 as of Friday, Dec. 20, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,274 issues advancing vs. 691 declining with 120 unchanged. The Drugs industry currently sits up 1.4% versus the S&P 500, which is up 0.6%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 6.0%, Regeneron Pharmaceuticals ( REGN), up 1.9%, Celgene Corporation ( CELG), up 1.8%, Amgen ( AMGN), up 1.8% and Biogen Idec ( BIIB), up 1.2%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. Jazz Pharmaceuticals ( JAZZ) is one of the companies pushing the Drugs industry higher today. As of noon trading, Jazz Pharmaceuticals is up $6.49 (5.7%) to $121.21 on heavy volume. Thus far, 1.3 million shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 752,700 shares. The stock has ranged in price between $118.16-$126.84 after having opened the day at $125.68 as compared to the previous trading day's close of $114.72. Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. Jazz Pharmaceuticals has a market cap of $6.6 billion and is part of the health care sector. The company has a P/E ratio of 21.2, above the S&P 500 P/E ratio of 17.7. Shares are up 115.4% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Jazz Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.